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 Malignant neoplasm is a condition that encompasses many disease states.  One 
unifying theme of these broadly diverse diseases is the requirement for angiogenesis, the 
formation of new blood vessels, as a prerequisite for tumor growth and metastasis.1 
Because abnormal cell proliferation requires sufficient blood supply, one method for 
slowing tumor growth may be altering tumor vasculature with angiogenic inhibitors.
 The Center for Drug Discovery, headed by Dr. Phillip Bowen, in collaboration 
with Dr. Jack Arbiser at the Emory University School of Medicine, have recently 
discovered that the natural compound, solenopsin A, is an effective inhibitor of 
angiogenesis.  Solenopsin A’s potent antiangiogenic activity was first identified using 
SVR proliferation assays.  To probe the mode of action in which solenopsin A was 
inhibiting angiogenesis, further studies were conducted in cells.  These studies suggest 
that solenopsin A is suppressing the phosphatidylinositol-3-kinase (PI3K)/Akt pathway 
by inhibiting a step in the signaling cascade upstream PI3K. 2
 The ultimate goal of this work is to develop an antiangiogenic drug based 
on solenopsin A.  Our immediate research objective, however, is to explore structure-
activity relationships for benzamide, ether, and amine side chain analogs of solenopsin A.  
Benzamide analogs of solenopsin A were first synthesized and screened for 
antiangiogenic activity using the SVR assays conducted at the Emory SOM.  The assay 
results indicate that none of the analogs tested were antiangiogenic.  To further explore 
the structural effects on angiogenic inhibition, ether side chain analogs were synthesized 
with varying alkyl chain lengths and the benzamide derivatives, previously synthesized, 
were reduced to amine side chain analogs. To assess the effect of n-alkyl chain length on 
angiogenic inhibition, one long-chain analog was also generated.  These ether, amine, and 
long-chain analogs are under consideration for testing using the SVR assays.
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CHAPTER I
INTRODUCTION
Solenopsis Invicta
 The red imported fire ant, Solenopsis invicta, is native to southern Brazil, 
Paraguay, and northern Argentina, but they have spread globally now to inhabit the 
United States, Canada, Australia, and China.3  These red imported fire ants, referred to as 
RIFAs, are known to have a strong, painful sting which in rare cases has resulted in 
anaphylactic shock and human death.4  More common human reactions to the stings 
include dermal necrosis, edema, and the formation of sterile pustules.5  S. invicta 
administers its sting by locking onto its prey with its crablike arms and repetitively 
inserting its stinger.  This allows for maximum delivery of its potent venom and 
immobilizes its prey.  While stinging, the ant also releases chemical signals to attract 
nearby ants to the prey. 
 Since S. invicta’s introduction to the U.S. in the 1920s, it has become a growing 
pest problem particularly in the south and midwest.  With few natural predators in North 
America, RIFAs have rapidly grown in numbers and now infest over 310 million acres of 
land, in 12 states, with the majority being in agricultural and residential areas.6  S. invicta 
is highly aggressive and colonies typically consist of 200,000 workers which swarm if 
threatened.  This has significantly disturbed the biodiversity of many ecosystems by 
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driving away or killing native ground dwelling species, such as lizards and ground-
nesting birds.7  S. invicta’s nesting in areas where colonies are more dense has caused 
additional ecological problems with land erosion, resulting largely from collapses of soil 
due to underground tunneling.8
 In the U.S., the economic impact of S. invicta is estimated to be $6 billion 
annually, with agricultural and energy sectors being most affected.9  The infestation of 
agricultural lands frequently leads to crop destruction and the killing of livestock.10         
S. invicta, for unknown reasons, is attracted to electrical sources and often damages 
electrical equipment by crawling into the wiring and causing shortages.  Many power 
companies have reoccurring difficulties with S. invicta infesting power distribution 
systems and converter boxers in residential areas.10  Farmers also report of S. invicta 
infestation of the electrical wiring of large farm equipment, which costs Texas farmers 
$190 million in equipment damages in 1998.11  Unfortunately the economic impact of S. 
invicta is not attributed to industry alone.  The same survey in 1998, found Texan 
households spent $526 million on pesticides aimed solely at fire ant control and in 
damage repairs.11
The Solenopsin Alkaloids
 The alkaloids produced in the poison glands of S. invicta make up over 99% of 
the venom and function as defensive compounds.  They consist of a mixture of 2-methyl 
2
6-n-alkyl (or -alkenyl) disubstituted piperidines and have also been shown to possess 
antibacterial, hemolytic, fungicidal, cytotoxic, and insecticidal properties.4, 12-14  The 
solenopsin alkaloids are classified depending on the length of their alkyl chain and the 
relative configuration of their substituents at the 2 and 6 positions of their piperidine rings 
(Figure 1). 
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Figure 1.  Alkaloid Components in the Venom of S. invicta
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 The solenopsins have a trans configuration about the 2 and 6 position of the 
piperidine ring, while the isosolenopsins are in cis configuration about the 2 and 6 
positions.  The stereochemistry of the trans solenopsins are specifically 2R,6R and the cis 
isosolenopsins are 2R,6S.15  Seven pairs of diastereoisomers have been identified with 
both trans and cis configurations about the piperidine ring.16,17  The first identified 
diastereoisomers were given trivial names based on the number of carbons in their alkyl 
chains.  These compounds are classified as A, B, and C having 11, 13, and 15 carbon 
alkyl chains, respectively (Figure 1).  The majority of the venom consists of the trans 
alkaloids, while the cis isoforms are present only in trace amounts.  The biological 
functions of the venom components have therefore been accredited to the trans isomers 
in numerous studies.18 - 20
 A recent study was conducted in an attempt to control S. invicta’s growing 
population.2  The goal of this project was to generate compounds that would inhibit the 
ant from producing the trans isomers, including solenopsin A.  Without the ability to 
produce its most abundant, defensive alkaloids, S. invicta would naturally fall prey to 
another organism.  The production of the solenopsins was hypothesized to be regulated 
by a negative feedback mechanism in its poison glands (Scheme 1).  Compounds were 
generated in an attempt to mimic the structure of solenopsin A in hopes they would 
interfere in the enzymatic regulation pathway to prevent its production.
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Scheme 1.  Enzymatic Inhibition of Solenopsin A Production
 The synthesized compounds (Figure 2) were tested using the SVR angiogenesis 
assay.2  Angiogenesis, the formation of blood vessels from preexisting vasculature, is a 
process that begins in the endothelial cells of the vasculature.  SVR assays using ras-
transformed endothelial cells are an effective and widely-used screening tool to probe a 
compound’s ability to inhibit angiogenesis in the initial stages of endothelial cell 
proliferation.  While none of the synthetic compounds were found to be antiangiogenic, 
solenopsin A did prove to be an effective inhibitor of angiogenesis.2 
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Figure 2.  Synthetic Analogs (from Previous Study) Subject to SVR Assays
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CHAPTER II
BACKGROUND
 The ability to inhibit angiogenesis has potentially important applications for the 
treatment of patients with various types of cancer.21  Angiogenic inhibitors have already 
been effective in treating ovarian cancer, 21 breast cancer,22 prostate cancer,23 and  
approximately 70 other diseases.  Cancer, termed medically as malignant neoplasms, is a 
general term describing many disease states when abnormal cells divide without control. 
The diversity of these disease states has made the development of treatment therapies 
difficult to achieve.  Interestingly, more than 85% of all cancer related deaths are 
attributed to solid tumors.24  Tumorigenesis, the formation of solid tumors, is then one 
unifying characteristic in this broadly diverse condition, making it an attractive 
physiological process to target.
Tumor-Induced Angiogenesis
 While tumorigenesis involves many biochemical processes, angiogenesis is the 
major prerequisite for tumor growth and metastasis, and therefore constitutes a pivotal 
point in the control of cancer progression.  Dividing malignant cells must stimulate 
7
angiogenesis in order to continue dividing.25  Angiogenesis is required because the 
rapidly dividing cells must obtain a sufficient supply of oxygen and nutrients while also 
being able to efficiently remove waste.  The vascularization of the malignant cell mass 
allows for continued, accelerated growth, and facilitates metastasis, the spread of 
cancerous cells to other areas of the body through both the lymphatic and circulatory 
systems. 25 
 Tumor-induced angiogenesis is initiated once the cell mass reaches 2 mm in 
diameter and begins to secrete pro-angiogenic growth factors which bind their receptor 
tyrosine kinases (RTKs) on the surface of the endothelial cells of nearby vasculature.  The 
primary RTKs involved in tumor-induced angiogenesis are the vascular endothelial 
growth factor receptors (VEGFRs).26  The VEGFR family of receptors consists of 
VEGFR-1, -2, and -3, with VEGFR-2 having the most significant role in angiogenesis.  
The pro-angiogenic growth factors affecting these receptors are the VEGF ligands 
(VEGF-A, -B, -C, -D, and -E), with the most active and abundant isoform being      
VEGF-A (VEGF165) often referred to simply as VEGF.27  
 Upon secretion from the tumorous cell mass, VEGF binds to 2 proximal 
VEGFR-2 on the surface of the endothelial cells of nearby vasculature.  Once bound, the 
receptors dimerize leading to autophosphorylation and subsequent activation of their 
tyrosine kinase domains.  Interaction of these kinase domains with intracellular substrate 
peptides activate a number of intracellular transduction pathways.  The major substrate 
peptide overstimulated in tumor-induced angiogenesis is phosphatidylinositol-3-kinase 
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(PI3K).  Once phosphorylated, PI3K then initiates a cascade of signaling events 
ultimately leading to the activation of Akt (or protein kinase B, PKB).  This is known as 
the PI3K/Akt pathway and is amplified in a number of malignancies.  Akt, once activated 
in the vascular endothelial cells, stimulates endothelial cell growth and proliferation 
which leads to the directional growth of blood vessels toward the malignant cell mass.28 
The PI3K-Akt Pathway
 Angiogenesis and tumorigenesis are predominately mediated through the 
increased activity of the PI3K/Akt intracellular pathway thus making it an attractive 
pharmacologic target.29  This pathway regulates cell survival, apoptosis, proliferation, 
cytoskeletal rearrangement, and protein synthesis, and is over expressed in both vascular 
endothelial cells and tumorous cells.25  While the tyrosine kinase domain of VEGFR-2 
induces PI3K activation in the vascular cells as described, other RTK activators of PI3K 
involved in tumorigenesis and tumor-induced angiogenesis include the fibroblast growth 
factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), insulin-like 
growth factor 1 receptors (IGF-1R), and the epidermal growth factor receptors 
(EGFRs).25 
 FGFR is activated by fibroblast growth factor (FGF) and is involved in embryonic 
development, the regulation of angiogenesis in well developed tissues, and in wound 
repair.  Platelet-derived growth factor (PDGF) is the ligand of PDGFR and is also 
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involved in wound repair, as well as the regulation of cellular development and 
proliferation.30  Insulin-like growth factor 1 (IGF-1) binds IGF-1R and though activation 
of PI3K, regulates series of intracellular signaling pathways that lead to cell growth and 
regulation of metabolism.  EGFRs are over expressed in the cells of solid tumors, 
specifically family members ErbB1 and HER1.31  This up-regulation overstimulates 
EGFR signaling which is initiated extracellularly by transforming growth factor 1 
(TGF-1) or endogenously by epidermal growth factor (EGF), and is observed in colon 
and lung cancers.32
 The amplification of intracellular signaling by these RTKs, beginning with PI3K 
activation, is a common occurrence in many malignancies and is outlined below (Figure 
3). Once activated, PI3K then phosphorylates phosphatidylinositol-3,4-diphosphate 
(PIP2) to produce phosphatidylinositol-3,4,5-triphosphate (PIP3), which acts as a second 
messenger leading to the subsequent activation of PKD1 and Akt.  Akt regulates protein 
synthesis, cell cycle progression, cellular metabolism, anti-apoptosis, and is the major 
downstream target of PI3K.33  The up-regulation of both PI3K and Akt, as well as 
mutations of PI3K have been observed in a number of malignancies, while inhibition of 
these second messengers has been shown to suppress both tumor growth and 
angiogenesis.  Mutations of PI3K have been found to occur in gastric, breast, ovarian, 
hepatocellular carcinoma, and colorectal cancers.34, 35 
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Figure 3. The PI3K/Akt Pathway
Small-Molecular-Weight Angiogenic Inhibitors
 Up-regulation of VEGF, the most potent stimulator of tumor-induced 
angiogenesis, leads to overstimulation of signaling through VEGFR-2, while up-
regulation of EGFRs, leads to amplification of EGF signaling in tumorigenesis.  The 
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receptors for EGF and VEGF are therefore popular targets for angiogenic inhibition, with 
drug-protein interactions occurring both extracellularly, effecting ligand binding domains, 
and intracellularly, acting on receptor/protein tyrosine kinases.  The direct binding of 
inhibitors to growth factors is another method of inhibition.24
 EGFR inhibition has been achieved with gefitinib (Iressa®) 36 and erlotinib 
(Tarceva®),37 while EGFR protein tyrosine kinase (PTK) inhibition has also been 
achieved with salicylamide analogs (Figure 4). These analogs also suppress VEGFR 
signaling by their direct interaction with VEGF.  The drug PTK787/ZK222584 is an 
receptor tyrosine kinase inhibitor of VEGFR-1,-2, and -3, and PDGFR (Figure 4).38  
Imatinib mesylate (Gleevec®) is also a receptor tyrosine kinase inhibitor of PDGFR beta 
and EGFR (Figure 4).39
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Figure 4.  Tyrosine Receptor Inhibitors
 Genistein has been shown to suppress both EGFR signaling in tumor cells, by 
inhibiting EGFR PTK, and VEGFR signaling in vascular endothelial cells, by binding 
directly to VEGF (Figure 5).40  Bevacizumab (Avastin®), although not a small-molecule, 
also suppresses VEGFR signaling by interacting directly with VEGF to inhibit receptor 
binding. Bevacizumab was the first angiogenic inhibitor to be approved by the U.S. Food 
and Drug Administration (F.D.A.) in 2003.24
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Figure 5.  VEGF Inhibitors
! PI3K and Akt inhibitors are also currently being used to treat various types of 
cancer.  The fungal metabolite, wortmannin, and the ether phospholipid, perifosine 
(Figure 6), both inhibit PI3K and represent the diversity of small-molecule angiogenic 
inhibitors, even among those acting on the same protein.41, 42  Perifosine has been shown 
to inhibit tumor growth in a number of malignancies while also enhancing the 
effectiveness of both chemotherapeutic drugs and radiation therapy.43  Miltefosine, 
another phospholipid ether (Figure 6), and perifosine also have inhibitory affects directly 
on Akt.44  The PI3K inhibitor, LY294002 (Figure 6), induces G1 cell cycle arrest and 
inhibits cell proliferation in ovarian cancer.45
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Figure 6.  PI3K/Akt Inhibitors
 Because microtubule formation, via tubulin polymerization, is essential for 
spindle formation and the separation of chromosomes required for cellular division, 
tubulin inhibitors, specifically those blocking polymerization/depolymerization, have 
been shown to inhibit the division/proliferation of malignant cells, as well as induce 
apoptosis.  The drug colchicine (Figure 7), has been shown to inhibit tubulin 
polymerization leading to malignant cell death, while paclitaxel and docetaxel (Figure 7) 
inhibit depolymerization by binding to microtubules thus preventing malignant cellular 
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division.46  Other promising tubulin inhibitors are the phenyl-3-(2-chloroetheyl)ureas 
(CEUs) which have been shown to inhibit tumor cell and vascular endothelial cell 
proliferation.  These compounds include 4-iodo-[3-(2-chloro-ethyl)ureido]phenyl (ICEU) 
and 4-tert-butyl-[3-(2- chloroethyl)ureido]phenyl (tBCEU) (Figure 7), and inhibit 
tumorigenesis and angiogenesis, by inhibiting microtubule formation via their formation 
of a covalent bond at the Cys239 of tubulin. They have also been shown to be 
antiangiogenic by inhibiting bFGF.24
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Previous Studies on Solenopsin A
 SVR angiogenic assays evaluate a compound’s ability to inhibit the proliferation 
of ras-transformed murine endothelial cells.  The ras gene is often mutated in a number 
of malignancies leading to overactive Ras proteins which effectively control cell 
proliferation and cellular growth. 47  Solenopsin A was administered at concentrations of 
1, 3, and 6 micrograms/ml into wells containing 10,000 SVR cells.  After 48 hrs they 
were counted and compared to a control to assess inhibition of proliferation.  The results 
showed solenopsin A inhibited cell proliferation in a dose-dependent manner (Figure 8).2  
Following these initial assays, a series of studies were conducted to assess solenopsin’s 
mode of action.  
Figure 8.  Previous SVR Assay Results of Solenopsin A
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 First, a series of in vitro studies were conducted to elucidate which protein(s) 
were being inhibited by solenopsin.  This was done by screening solenopsin A against 28 
protein kinases including PI3K, purified PI3K, and Akt.  Solenopsin A was found to have 
no affect on PI3K.  By measuring the production of PIP3 from PIP2 in a cell-free assay, 
solenopsin was also found to have no affect on purified recombinant PI3K p110alpha/
p85alpha, nor did solenopsin inhibit PKD1 activity, one of several activators of Akt.  Akt 
activity was, however, selectively inhibited by 50% when assayed with solenopsin A at a 
concentration of 10 micro-molar.2
 A FOXO1a export assay on cells treated with solenopsin A was used to assess Akt 
inhibition in cells.  Akt, the major downstream target of PI3K, phosphorylates numerous 
proteins involved in angiogenesis including the forkhead family of transcription factors 
(FKHD/FOXO).  Once the FOXO transcription factors are phosphorylated by Akt, they 
are exported from the nucleus to the cytoplasm.  Solenopsin was found to inhibit the 
transport of FOXO1a into the cytoplasm which suggested Akt inhibition. PI3K/Akt 
inhibition assays were also conducted in cells to determine the affects on PDGF 
stimulated signaling and insulin induced signaling.  PDGF signaling was unaffected by 
solenopsin, however solenopsin did prevent PI3K activation in insulin stimulated cells 
without affecting IRS1 phosphorylation.  Solenopsin’s inhibition of PI3K, and subsequent 
downstream signaling events, without inhibiting IRS1 strongly suggested it was 
suppressing the PI3K/Akt pathway by inhibiting a step downstream of IRS1 and 
upstream of PI3K.2 
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CHAPTER III
RESULTS AND DISCUSSION
 In order to explore the structure-activity relationships of solenopsin A analogs and 
their ability to inhibit angiogenesis, four groups of synthetic derivatives were generated. 
The compounds synthesized were based on the organic structure of our lead compound 
solenopsin A, in combination with common structural features of effective F.D.A. 
approved angiogenic inhibitors and those in clinical development.  Consideration was 
given to features including common functional groups, aromatic/aliphatic regions, 
functional groups of attachment between aromatic/aliphatic regions, and alkyl chain 
length.  Because the specific affecter protein(s) of solenopsin A has yet to be determined, 
we explored the commonalities of protein-specific angiogenic inhibitors including 
tyrosine kinase inhibitors, VEFG inhibitors, and tubulin inhibitors.  Using this approach, 
four groups of compounds were synthesized including benzamide analogs, an amine 
analog, ether analogs, and a long-chain n-alkyl analog (Figure 9). 
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Figure 9. Overview of Synthesis
Synthesis of Solenopsin A Analogs
 
 The major structural similarity of effective small-molecule angiogenic inhibitors 
consists of two aromatic regions connected by amide and/or amine functional groups.24  
The amide functional group of attachment can be seen in the tyrosine kinase inhibitor 
Gleevec (Figure 4) and the VEGF inhibitors salicylamide, salicylamide analog (Figure 5), 
and Bay 43-9006 (Figure 10).  The tubulin inhibitors ICEU, tBCEU, LY295501, 
Sulofenur, and diarylsulfonylurea-2b also possess the amide functional group of 
attachment (Figures 7, 10).  Several of these inhibitors, including Gleevec (Figure 4), 
salicylamide and salicylamide analog (Figure 5), and diarylsulfonylurea-2b (Figure 10), 
also contain benzamides as a common structural feature.  This structural commonality 
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was introduced into our lead compound to generate the benzamide analogs by 
replacement of the undecyl side chain at the 6 position of solenopsin A’s piperidine ring 
with substituted benzamides, and elimination of the methyl group at the 2 position of 
solenopsin A.
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Figure 10.  Small-Molecule Inhibitors with Amide Functional Groups
 The benzamide compounds were synthesized as indicated in Scheme 2 via acyl 
exchange reactions in an aprotic solvent.  1-Boc-2-(aminomethyl)piperidine was reacted 
with various benzoyl chloride reagents to generate the compounds.  1-Boc-2-
(aminomethyl)piperidine was chosen as the starting material due to the stability of the 
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Boc protecting group, while the benzoyl chloride reactant was varied depending on the 
desired product.
Scheme 2.  Synthesis of Benzamide Analogs
 The selectivity of the nucleophilic attack on the carbonyl carbon of the benzoyl 
chloride by the nitrogen of the primary amine resulted in few side products and relatively 
high yields.  Initial attempts showed using 1.5 equivalents of the Boc protected starting 
material and 1.0 equivalent of benzoyl chloride resulted in the highest yields (60% - 
80%).  The reactions were conducted by chilling a solution of 1-Boc-2-
(aminomethyl)piperidine in THF in an ice bath, followed by the addition of NaOH (2.0 
M).  The solution was stirred and the benzoyl chloride reagent was added.  The reaction 
was allowed to reach room temperature while stirring for 2.5 hrs.  The reaction mixture 
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was then extracted and the organic layer dried over MgSO4.  Mixtures were purified 
using either column chromatography or preparative TLC.  Solvents were evaporated 
following purification, and deprotection of the resulting residue was achieved by adding 
HCl in ether.  Evaporation of solvents yielded the final product as either a white 
precipitate or as a yellowish, oily residue.  To insure the stability of the compounds, 
several benzamide analogs were converted into water soluble hydrochloride salts 
following acidic removal of the Boc protecting group.  This was achieved by dissolving 
the oil residues in a minimal amount of DCM and adding anhydrous ether (or anhydrous 
hexane) drop wise until precipitation occurred.  The benzamide compounds that were 
generated are shown in Figure 11.
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Figure 11. Synthetic Benzamide Analogs of Solenopsin A
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 The synthetic benzamide derivatives of solenopsin A were assayed against SVR 
endothelial cells and none were found to be antiangiogenic.  Following these assays, the 
benzamide analogs were reduced from their amide connecting group to generate diamine 
analogs, as described in Scheme 3.  The amine analogs were synthesized based on the 
tyrosine kinase inhibitors Iressa, Tarceva, PTK787/ZK222584, and Gleecec which all 
possess amine function groups of attachment (Figure 4).  Although several of the 
benzamide analogs (Benzamides 1-6) were reduced, only Amine 2 could be isolated 
(Figure 12).
Scheme 3. Synthesis of Amine Analogs
Figure 12.  Synthetic Amine Analog of Solenopsin A
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 The benzamide analogs were first dissolved in anhydrous THF (or ether) under 
argon pressure, followed by the addition of 5 eq of lithium aluminum hydride.  The 
reactions were refluxed for 12 - 24 hrs, and TLC analysis was used to confirm reaction 
completion using 5% - 10% MeOH in dichloromethane as the solvent system.  The 
excess LAH was then quenched using either a Rochelle’s salt solution or by conducting a 
Fieser workup.
 When an aluminum emulsion resulted following the initial reaction, the emulsion 
was separated using a saturated aqueous solution of Rochelle’s salt (sodium potassium 
tartrate).  This was achieved by cooling the reaction solution to 0 OC and quenching the 
excess LAH by adding ethyl acetate drop wise while stirring.  The ice bath was then  
removed and the Rochelle’s salt solution was added to the reaction mixture and stirred for 
1 -3 hrs.  The reaction mixture was then diluted with DCM and extracted.  The solvents 
were evaporated in the rotovap to yield the final amine product.  Initial attempts at 
extraction often resulted in reformation of the emulsion which resulted in loss of the 
amine product.
 A Fieser workup was also conducted on several of the benzamide reductions.  
This was done by quenching the initial reaction mixture by slowly adding 0.2 ml of H2O, 
followed by the addition of 0.2 ml of 15% NaOH, followed by 0.6 ml of H2O.  The 
solution was then stirred on ice for 1 hr and resulted in formation of a granular salt.  The 
salts were removed by vacuum filtration and washed with ether.  The reaction mixture 
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was diluted with DCM and extracted.  Solvents were evaporated in the rotovap to yield 
the final amine product.
 The ether analogs were generated by removal of the 2-methyl of solenopsin A’s 
piperidine ring and substitution at the 6 position with ether functional groups of 
attachment, having n-alkyl chain lengths of 2 and 3 carbons.  A benzoyl protected alcohol 
starting material was reacted with alkyl iodides of various alkyl chain length to generate 
the ether compounds (Figure 13).  The starting material’s piperidine nitrogen was 
protected with the benzoyl group to allow for more accurate TLC analysis and because of 
its stability in basic solutions. 
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Figure 13.  Synthetic Ether Analogs of Solenopsin A
 The ether analogs were synthesized using base catalyzed ether formation 
reactions, followed by acidic deprotection as indicated in Scheme 4. This was achieved 
by first dissolving the benzoyl protected starting material, C13H12NO2, in anhydrous THF 
on ice, while under Ar pressure.  t-BuOK (2 eq) was then added followed by the addition 
of the alkyl iodide (2 eq) and the reaction was stirred for 2 - 4 hrs.  The reaction mixture 
was diluted with DCM, extracted, and dried over MgSO4.  The drying agent was removed 
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by gravity filtration and TLC analysis assessed reaction completion.  The reaction 
mixture was then purified by column chromatography using a solvent system of 
hexanes:EtOAc.  Solvents were evaporated and removal of the benzoyl protecting group 
was achieved by adding MeOH to the resulting residue, followed by the addition of 
concentrated HCl.  The reaction was refluxed for 24 hrs and the reaction solution 
neutralized with NaHCO3 and the extracted.  The organic layer was dried and gravity 
filtered to remove the drying agent.  Solvents were removed in the rotovap to yield the 
final product as a brown precipitate.
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Scheme 4.  Synthesis of Ether Analogs
 One long-chain n-alkyl derivative of solenopsin A was generated (Figure 14) by 
the reduction of 2-methyl-6-nonadecylpyridine to form 2-methyl-6-nonadecylpiperidine 
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as described in scheme 5.  Five attempts at reduction, using increased reaction times, 
finally resulted in isolation of the desired product (Figure 14).
Figure 14.  Synthetic Long-Chain n-Alkyl Analog of Solenopsin A
 The reduction was achieved via catalytic hydrogenation by adding Pd/C and Rh/C 
to a solution of 2-methyl-6-nonadecylpyridine in absolute ethanol.  The reaction was 
shaken under 55 psi for 30 hr in a parr hydrogenator.  Catalyst were removed by filtering 
through a plug of celite using 5% MeOH in DCM.  The reaction mixture was then 
purified by column chromatography using a minimal amount of silica and varying the 
solvent system between 5-10% MeOH in DCM, depending on separation during TLC 
analysis.
Scheme 5.  Hydrogenation of 2-methyl-6-nonadecylpyridine
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Experimental Data
General Procedures.  All reagents, catalysts, and starting materials were purchased from 
Sigma Aldrich.  Extractions of initial reaction mixtures were conducted using DCM 
unless stated otherwise.  Following extraction, TLC analysis was done using Whatmen 
silica gel plates and reaction completion was determined by visualization under UV light. 
Purification, using silica gel 60 (230 - 400 mesh), was achieved by filtration through a 
plug of silica,  column chromatography, or preparative TLC.  All solvents were reagent 
grade, and the solvent systems were 1:1 ethyl acetate to hexanes unless otherwise 
indicated.  1H NMR of protected analogs were taken after purification and before 
deprotecting.  Final products were concentrated by evaporation of solvents using a rotary 
evaporator and subject to 1H NMR and mass spectrometry to confirm purity.
3,5-difluoro-N-(piperidin-2-ylmethyl)benzamide (BENZAMIDE 1).  A solution of tert-
butyl 2-(aminomethyl)piperidine-1-carboxylate (50 mg, 0.234 mmol, 1.5 eq) in DCM 
(3.0 mL) was chilled in ice bath, followed by the addition of NaOH (2.0 M, 1.0 ml).  The 
solution was stirred and 3,5-difluorobenzoyl chloride (0.0014 ml, 0.115 mmol, 1.0 eq) 
was added.  The reaction was allowed to reach room temperature as the mixture 
continued stirring for 2.5 hrs.  The reaction mixture was then diluted by the addition of 
DCM (10 ml) and extracted with water (2 x 1.0 ml).  The DCM was dried over MgSO4 
(1.0 g) and filtered through a plug of Silica gel.  The DCM was then evaporated using a 
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rotovap for 4.0 hrs and the residue which formed was dried under vacuum for 2 days. 
Deprotection was conducted by adding HCl in ether (2.0 M, 2.0 ml) to the residue and 
stirring for 3 days at room temperature.  Ether was then evaporated using the rotovap to 
yield 25 mg of product, as a white precipitate (86%).
N-(piperidin-2-ylmethyl)-3-(trifluoromethyl)benzamide hydrochloride 
(BENZAMIDE 2).  tert-butyl 2-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 
mmol, 1.5 eq) in THF (1 ml), was chilled in an ice bath, followed by the addition of 
NaOH (2.0 M, 0.9 ml).  The solution was stirred and 3-(trifluoromethyl)benzoyl chloride 
(0.0047 ml, 0.311 mmol, 1.0 eq) was added.  The reaction mixture was allowed to reach 
room temperature while stirring overnight.  The mixture was then diluted by the addition 
of dichloromethane (15 ml) and extracted with water (2 x 3.0 ml).  The DCM layer was 
dried over MgSO4 (1.0 g) and filtered through a plug of Silica gel.  Solvents were 
removed by rotary evaporation.  TLC analysis confirmed further purification was need 
and this was accomplished using preparative TLC.  The residue was dissolved in DCM 
(2.0 ml) and applied to a preparative TLC plate.  A 1:1 hexane:EtOAc solvent system 
allowed for optimal separation of the reaction mixture.  The desired portion was scraped 
from the TLC plate and stirred in EtOAc (25.0 ml) for 30 min.  The EtOAc was then 
vacuum filtered to remove Scilica and evaporated in the rotovap to form an oil residue.  
The residue was dried under vacuum for 2 days.  Deprotection was conducted by adding 
HCl in ether (2.0 M, 3.0 ml) to the residue and stirring at room temperature overnight.  
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Ether was then evaporated using the rotovap overnight without heat which formed 52 mg 
of an oil product (58.5%).  The residue was converted into a water soluble hydrochloride 
salt to insure stability of the compound.  This was achieved by dissolving the oil residue 
in a minimal amount of dichloromethane (~0.0020 ml) and adding anhydrous ether drop 
wise until precipitation occurred.  Solvents where then removed by rotary evaporation 
and purity assessed via 1H NMR.
N-(piperidin-2-ylmethyl)-2-naphthamide hydrochloride (BENZAMIDE 3).  A 
solution of tert-butyl 2-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 
eq) in THF (1 ml) was chilled in an ice bath, followed by the addition of NaOH (2.0 M, 
0.5 ml).  The solution was stirred and beta-naphthoyl chloride (59.1 mg, 0.311 mmol, 1.0 
eq) was added.  The reaction was allowed to reach room temperature while stirring for 4 
hrs.  The reaction mixture was then diluted by the addition of ether (20 ml) and extracted 
with water (2 x 1.0 ml).  The ether was dried over MgSO4 (1.0 g), and the mixture was 
purified by column chromatography.  The solvents were then removed by rotary 
evaporation and the residue which formed was dried under vacuum overnight. 
Deprotection was conducted by adding HCl in ether (2.0 M, 3.0 ml) to the residue and 
stirring at room temperature overnight.  Ether was then evaporated using the rotovap to 
leave an oily residue (47 mg, 56.6%).  To achieve solid product, the residue was 
dissolved in DCM (0.0020 ml) and anhydrous ether was added drop wise.  The 
precipitate was then stored under vacuum overnight.
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N-(piperidin-2-ylmethyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride 
(BENZAMIDE 4 & BENZAMIDE G).  A solution of tert-butyl 2-
(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) in THF (1.0 ml) 
was chilled on ice, followed by the addition of NaOH (2.0 M, 0.5 ml).  The solution was 
stirred whiled adding 3,5-bis(trifluoromethyl)benzoyl chloride (0.0057 ml, 0.311 mmol, 
1.0 eq).  The reaction ran for 4 hrs and was maintained at 0 oC.  The reaction mixture was 
then diluted by the addition of DCM (10 ml) and extracted with water (2 x 1.0 ml).  The 
DCM was dried over MgSO4 (1.0 g) and filtered through a plug of Silica gel.  The 
reaction mixture was purified by column chromatography using 1:1 hexane:ethyl acetate 
solvent system.  Solvents were removed by rotary evaporation and the residue was kept 
under vacuum for 2 days.  The Boc protecting group was removed by adding HCl in ether 
(2.0 M, 2.0 ml) to the residue and stirring for 3 days at room temperature.  Ether was then 
evaporated using the rotovap and a white precipitate (40 mg, 36%) was formed.
4-chloro-N-(piperidin-2-ylmethyl)benzamide hydrochloride (BENZAMIDE 5).  tert-
butyl 2-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) was 
dissolved in THF (1.0 mL) and NaOH (2.0 M, 0.5 ml) was added.  The solution was 
stirred and cooled in an ice bath while adding 4-chlorobenzoyl chloride (0.0040 ml, 0.311 
mmol, 1.0 eq).  The reaction was allowed to reach room temperature while running 
overnight.  The reaction mixture was then diluted by the addition of DCM (10 ml) and 
extracted with water (2 x 1.0 ml).  The DCM was dried over MgSO4 (1.0 g) and filtered 
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through a plug of Silica gel.  Further purification was achieved by column 
chromatography using 1:1 hexane:ethyl acetate solvent system.  The residue was kept 
under vacuum for 2 days to remove solvents.  The Boc protecting group was removed by 
addition of HCl in ether (2.0 M, 2.0 ml) to the residue and stirring for 3 days at room 
temperature.  Ether was removed by storing under vacuum for 24 hrs, and a white 
precipitate (51mg, 64.9%) was formed .
2-chloro-N-(piperidin-2-ylmethyl)benzamide hydrochloride (BENZAMIDE 6).  
NaOH (2.0 M, 0.5 ml) was added to a solution of tert-butyl 2-(aminomethyl)piperidine-1-
carboxylate (100 mg, 0.467 mmol, 1.5 eq) dissolved in THF (1.0 ml).  The solution was 
stirred and cooled in an ice bath while adding 2-chlorobenzoyl chloride (0.0040 ml, 0.311 
mmol, 1.0 eq).  The reaction was allowed to reach room temperature while running 
overnight.  The reaction mixture was then diluted by the addition of DCM (10 ml) and 
extracted with water (2 x 1.0 ml).  The DCM was dried over MgSO4 (1.0 g) and filtered 
through a plug of Silica gel.  Solvents were removed by rotary evaporation and TLC 
analysis confirmed that further purification was needed.  The residue was dissolved in 
DCM (2.0 ml) and applied to a preparative TLC plate.  A 1:1 hexane:EtOAc solvent 
system allowed for optimal separation of the reaction mixture.  The desired portion was 
scraped from the TLC plate and stirred in EtOAc (15.0 ml) for 30 min.  Following 
vacuum filtration the EtOAc was evaporated in the rotovap and the residue was kept 
under vacuum for 2 days. HCl in ether (2.0 M, 2.0 ml) was added to the residue and 
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stirred for 3 days at room temperature.  Ether was removed by storing under vacuum 
overnight, and a white precipitate (56 mg, 71.4%) was formed. 
2,6-dichloro-N-(piperidin-2-ylmethyl)benzamide (BENZAMIDE 7).  tert-butyl 2-
(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) was dissolved in 
THF (1.0 ml) and NaOH (2.0 M, 0.5 ml) was added.  The solution was stirred and cooled 
in an ice bath and 2,6-dichlorobenzoyl chloride (0.0045 ml, 0.311 mmol, 1.0 eq) was 
added.  The reaction was allowed to reach room temperature while running for 12 hrs.  
DCM (10 ml) was then added to dilute the reaction mixture following extraction with 
water (2 x 1.0 ml).  The DCM was dried over MgSO4 (1.0 g) and filtered through a plug 
of Silica gel. TLC analysis confirmed that further purification was needed.  The reaction 
mixture was concentrated via rotary evaporation and dissolved in DCM (1.0 ml) before 
being applied to a preparative TLC plate.  A 1:1 hexane:EtOAc solvent system allowed 
for optimal separation of the reaction mixture.  The desired portion was scraped from the 
TLC plate and stirred in EtOAc (15.0 ml) for 30 min.  Silica was removed by vacuum 
filtration and the EtOAc was evaporated in the rotovap.  The residue was kept under 
vacuum for 2 days.  HCl in ether (2.0 M, 2.0 ml) was then added to the residue and 
stirred for 3 days at room temperature.  The ether was removed by storing under vacuum 
overnight, and a white precipitate (30 mg, 33.6%) was formed.
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3-fluoro-N-(piperidin-2-ylmethyl)benzamide (BENZAMIDE 8).  NaOH (2.0 M, 0.5 
ml) was added to a solution of tert-butyl 2-(aminomethyl)piperidine-1-carboxylate (100 
mg, 0.467 mmol, 1.5 eq) dissolved in THF (1.0 ml).  The solution was stirred and cooled 
in an ice bath and 3-fluorobenzoyl chloride (0.0038 ml, 0.311 mmol, 1.0 eq) was added.  
The reaction was allowed to reach room temperature while running overnight.  The 
reaction mixture was then diluted with DCM (10 ml) and extracted with water (2 x 1.0 
ml).  The DCM was dried over MgSO4 (1.0 g) and gravity filtered to remove the drying 
agent.  The reaction mixture was concentrated via rotary evaporation and dissolved in 
DCM (1.0 ml).  Purification was achieved by prep TLC using a 1:1 hexane:EtOAc 
solvent system.  Solvents were evaporated in the rotovap and the residue was kept under 
vacuum for 2 days.  HCl in ether (2.0 M, 2.0 ml) was then added to the residue and 
stirred for 3 days at room temperature.  Ether was removed by storing under vacuum 
overnight, and a white precipitate (50 mg, 68.0%) was formed.
3-chloro-N-(piperidin-2-ylmethyl)benzamide hydrochloride (BENZAMIDE 9).  tert-
butyl 2-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) was 
dissolved in THF (1.0 ml) and NaOH (2.0 M, 0.5 ml) was added.  The solution was 
stirred and cooled on ice while 3-chlorobenzoyl chloride (0.0040 ml, 0.311 mmol, 1.0 eq) 
was added.  The reaction was allowed to reach room temperature while running for 12hrs. 
DCM (10 ml) was then added to dilute the reaction mixture following extraction with 
water (2 x 1.0 mL).  The DCM was dried over MgSO4 (1.0 g) and vacuum filtered to 
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remove the drying agent.  The reaction mixture was concentrated via rotary evaporation.  
Purification was achieved by prep TLC using a 1:1 hexane:EtOAc solvent system.  
Solvents were evaporated in the rotovap and the residue was kept under vacuum for 2 
days.  HCl in ether (2.0 M, 2.0 ml) was then added to the residue and stirred for 3 days at 
room temperature.  Ether was removed by storing under vacuum and 55 mg of an oil 
product formed (70.0%).  To achieve solid product, the residue was dissolved in DCM 
(0.0020 ml) and anhydrous ether was added drop wise.  The precipitate was then stored 
under vacuum overnight.
2,6-difluoro-N-(piperidin-2-ylmethyl)benzamide (BENZAMIDE 10).  To a solution of 
tert-butyl 2-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) 
dissolved in THF (1.0 ml), NaOH (2.0 M, 0.5 ml) was added. The solution was stirred 
and cooled on ice while 2,6-difluorobenzoyl chloride (0.0039 ml, 0.311 mmol, 1.0 eq) 
was added.  The reaction was allowed to reach room temperature while running 
overnight.  The reaction mixture was diluted with DCM (10 ml) and extracted with water 
(2 x 1.0 ml).  The DCM was dried over MgSO4 (1.0 g) and vacuum filtered to remove the 
drying agent.  The reaction mixture was concentrated via rotary evaporation and subject 
to prep TLC using a 1:1 hexane:EtOAc solvent system.  The solvents were removed by 
rotary evaporation and the residue was kept under vacuum for 2 days.  TLC analysis 
confirmed that further purification was required.  This was achieved by column 
chromatography.  Deprotection was achieved using HCl in ether (2.0 M, 2.0 ml) while 
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stirring for 3 days at room temperature.  The ether was removed by storing under vacuum 
overnight, and 41 mg of a white solid product was formed (51.8%).
3,4-dichloro-N-(piperidin-2-ylmethyl)benzamide hydrochloride (BENZAMIDE 11).  
tert-butyl 2-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) was 
dissolved in THF (1.0 ml) and NaOH (2.0 M, 0.5 ml) was added.  The solution was 
stirred on ice while 3,4-dichlorobenzoyl chloride (65.14 mg, 0.311 mmol, 1.0 eq) was 
added.  The reaction was allowed to reach room temperature while running overnight. 
DCM (10 ml) was then added to dilute the reaction mixture following extraction with 
water (2 x 1.0 ml).  The DCM was dried over MgSO4 (1.0 g) and vacuum filtered to 
remove the drying agent.  The reaction mixture was concentrated by rotary evaporation. 
Purification was achieved by column chromatography.  Solvents were evaporated in the 
rotovap and the residue was kept under vacuum for 2 days.  HCl in ether (2.0 M, 2.0 ml) 
was then added to the residue and stirred for 3 days at room temperature to remove the 
boc protecting group.  Ether was evaporated by storing under vacuum overnight, and a 
white solid formed (67 mg, 75.0%).
N-(piperidin-2-ylmethyl)benzamide hydrochloride (BENZAMIDE 12).  NaOH (2.0 
M, 0.5 mL) was added to a solution of tert-butyl 2-(aminomethyl)piperidine-1-
carboxylate (100 mg, 0.467 mmol, 1.5 eq) in THF (1.0 ml).  The solution was stirred on 
ice while benzoyl chloride (0.0040 ml, 0.311 mmol, 1.0 eq) was added.  The reaction was 
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allowed to reach room temperature while running overnight. DCM (10 ml) was then 
added to dilute the reaction mixture following extraction with water (2 x 1.0 ml).  The 
DCM was dried over MgSO4 (1.0 g) and vacuum filtered to remove the drying agent. The 
reaction mixture was concentrated by rotary evaporation and purification was achieved 
by prep TLC using a 1:1 hexane:EtOAc solvent system.  Solvents were evaporated in the 
rotovap and the residue was kept under vacuum for 2 days.  HCl in ether (2.0 M, 2.0 ml) 
was then added to the residue and stirred for 3 days at room temperature.  Ether was 
evaporated by storing under vacuum overnight resulting in a white solid product (25 mg, 
36.8%).
4-fluoro-N-(piperidin-2-ylmethyl)benzamide (BENZAMIDE 13).  To a solution of tert-
butyl 2-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) dissolved 
in THF (1.0 ml), NaOH (2.0 M, 0.5 ml) was added.  The solution was stirred on ice while 
4-fluorobenzoyl chloride (0.0040 ml, 0.311 mmol, 1.0 eq) was added. The reaction was 
allowed to reach room temperature while running overnight. DCM (10 ml) was then 
added to dilute the reaction mixture following extraction with water (2 x 1.0 ml).  The 
DCM was dried over MgSO4 (1.0 g) and vacuum filtered to remove the drying agent. The 
reaction mixture was concentrated by rotary evaporation and purified using prep TLC. 
Solvents were removed by rotary evaporation and the residue was kept under vacuum for 
2 days. HCl in ether (2.0 M, 2.0 ml) was then added to the residue and the reaction 
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mixture stirred for 3 days at room temperature.  Ether was removed by storing under 
vacuum overnight to form a white solid product (58 mg, 78.9%).
3,4-difluoro-N-(piperidin-2-ylmethyl)benzamide hydrochloride (BENZAMIDE 13B). 
NaOH (2.0 M, 0.5 ml) was added to a solution of tert-butyl 2-(aminomethyl)piperidine-1-
carboxylate (100 mg, 0.467 mmol, 1.5 eq) dissolved in THF (1.0 ml). The solution was 
stirred on ice while 3,4-diflorobenzoyl chloride (64 mg, 0.311 mmol, 1.0 eq) was added.  
The reaction was allowed to reach room temperature while running overnight.  DCM (10 
ml) was then added to dilute the reaction mixture following extraction with water (2 x 1.0 
ml).  The DCM was dried over MgSO4 (1.0 g) and gravity filtered to remove the drying 
agent.  The reaction mixture was concentrated by rotary evaporation.  Purification was 
achieved by column chromatography and solvents were evaporated in the rotovap.  The 
residue was kept under vacuum for 2 days.  HCl in ether (2.0 M, 2.0 ml) was then added 
to the residue and stirred for 3 days at room temperature to remove the boc protecting 
group.  Ether was evaporated by storing under vacuum for 2 days and a white solid 
product (50 mg, 63.2%) was formed.
3,4-dimethoxy-N-(piperidin-2-ylmethyl)benzamide (BENZAMIDE H).  A solution of 
tert-butyl 2-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) was 
dissolved in THF (1.0 ml) and NaOH (2.0 M, 0.5 ml) was added.  The solution was 
stirred on ice while 3,4-dimethoxybenzoyl chloride (62.39 mg, 0.311 mmol, 1.0 eq) was 
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added.  The reaction was allowed to reach room temperature while running overnight. 
DCM (10 ml) was then added to dilute the reaction mixture following extraction with 
water (2 x 1.0 ml).  The DCM was dried over MgSO4 (1.0 g) and vacuum filtered to 
remove the drying agent.  The reaction mixture was concentrated by rotary evaporation. 
Purification was achieved by column chromatography.  Solvents were evaporated in the 
rotovap and the residue was kept under vacuum for 2 days. HCl in ether (2.0 M, 2.0 ml) 
was then added to the residue and stirred for 3 days at room temperature to remove the 
boc protecting group.  Ether was evaporated by storing under vacuum overnight and a 
white solid ( 70 mg, 80.8%) was formed. 
2,4-dichloro-N-(piperidin-2-ylmethyl)benzamide (BENZAMIDE J). tert-butyl 2-
(aminomethyl)piperidine-1-carboxylate (100 mg, 0.467 mmol, 1.5 eq) was dissolved in 
THF (1.0 ml) followed by the addition of NaOH (2.0 M, 0.5 ml). The solution was stirred 
on ice while 2,4-dichlorobenzoyl chloride (0.0038 ml, 0.311 mmol, 1.0 eq) was added. 
The reaction was kept at 0 OC and stirred for 4 hrs. DCM (10 ml) was then added to 
dilute the reaction mixture following extraction with water (2 x 1.0 ml).  The DCM was 
dried over MgSO4 (1.0 g) and vacuum filtered to remove the drying agent. The reaction 
mixture was concentrated by rotary evaporation and purified using prep TLC.  Solvents 
were removed by rotary evaporation and the residue was kept under vacuum for 2 days. 
HCl in ether (2.0 M, 2.0 ml) was then added to the residue and the reaction mixture 
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stirred for 3 days at room temperature.  Ether was evaporated by storing under vacuum 
overnight to form a white solid product (47 mg, 52.6%).
2-(((3-(trifluoromethyl)benzyl)amino)methyl)piperidin-1-ium (AMINE 2).  The 
previously synthesized compound, N-(piperidin-2-ylmethyl)-3-(trifluoromethyl)-
benzamide (BENZAMIDE 2) (21 mg), was suspended in 6.8 ml of anhydrous ether.  
Lithium aluminum hydride (19 mg) was added to the solution and the reaction was 
refluxed for 24 hrs.  TLC analysis assess reaction completion using 5 % MeOH in 
dichloromethane as the solvent system.  The reaction solution was chilled to 0 OC and 
quenched by slowly adding ethyl acetate drop wise while stirring.  An aluminum 
emulsion resulted.  To the emulsified reaction mixture, 5 drops of DI H2O were added, 
followed by 5 drops of 2M NaOH, followed by 15 drops of DI H2O while stirring in an 
ice bath for 1 hr.  Separation of the emulsion resulted in formation of a granular salt. The 
reaction mixture was filtered under vacuum to remove salts and washed with ether.  The 
reaction mixture was then diluted further with DCM (10 ml).  The complete removal of 
H2O was achieved by drying 5 times over MgSO4 (1.0 g) and followed by vacuum 
filtration to remove the drying agent.  The evaporation of solvents in the rotovap yielded 
10 mg of the final amine product.  
2-(ethoxymethyl)piperidin-1-ium (ETHER 2).  The benzoyl protected starting material, 
C13H12NO2, (310 mg, 1.41 mmol) was dissolved in 5 ml of anhydrous THF on ice while 
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under Ar pressure. t-BuOK (317 mg, 2.82 mmol, 2 eq) was then added, followed by the 
addition of of iodoethane (0.664 cc, 2.82 mmol, 2 eq).  The reaction solution was stirred 
for 2.5 hrs and then extracted with 10 ml of DCM & washed twice with 5 ml of DI H2O. 
The organic layer was dried over 1 g of MgSO4 and gravity filtered to removed the 
drying agent.  TLC analysis assessed reaction completion.  The reaction mixture was then 
purified by column chromatography using a 1:1, hexanes:EtOAc solvent system.  
Solvents were removed via rotatory evaporation.  Deprotection was achieved by adding 5 
ml of MeOH to the resulting residue, followed by the addition of 2.5 ml of conc HCl and 
refluxing for 30 hrs.  Following reflux, the reaction solution was neutralized by the 
addition of NaHCO3 until litmus testing indicated basicity of the solution.  The organic 
layer was then extraction with 10 ml of DCM, washed twice with 5 ml of DI H2O, and 
dried over 1 g of MgSO4.  Gravity filtration removed drying agent and solvents were 
removed in the rotovap to yield final product as a brownish precipitate.
2-(propoxymethyl)piperidine (ETHER 3).  The benzoyl protected starting material, 
C13H12NO2, (310 mg, 1.41 mmol) was dissolved in 5 ml of anhydrous THF on ice while 
under Ar pressure.  t-BuOK (317 mg, 2.82 mmol, 2 eq) was then added, followed by the 
addition of of iodopropane (0.274 cc, 2.82 mmol, 2 eq).  The reaction solution was stirred 
for 2.5 hrs and then extracted with 10 ml of DCM & washed twice with 5 ml of DI H2O. 
The organic layer was dried over 1 g of MgSO4 and gravity filtered to removed the 
drying agent. TLC analysis assessed reaction completion.  The reaction mixture was then 
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purified by column chromatography using a 1:1, hexanes:EtOAc solvent system.  
Solvents were removed via rotatory evaporation.  Deprotection was achieved by adding 5 
ml of MeOH to the resulting residue, followed by the addition of 2.5 ml of conc HCl and 
refluxing for 30 hrs.  Following reflux, the reaction solution was neutralized by the 
addition of NaHCO3 until basicity of the solution was pH of 8.  The organic layer was 
then extraction with 10 ml of DCM, washed twice with 5 ml of DI H2O, and dried over 1 
g of MgSO4.  Gravity filtration removed drying agent and solvents were removed in the 
rotovap to yield final product as a brownish precipitate.
2-methyl-6-nonadecylpiperidine (Long-Chain Analog).  To a solution of 2-methyl-6-
nonadecylpyridine (70 mg) dissolved in absolute ethanol (8 ml), Pd/C (20 mg) was added 
followed by the addition of Rh/C (50 mg).  The solution was then shaken under 55 psi for 
30 hrs.  To remove the catalyst, the reaction mixture was filtered through a plug of celite 
using 5% MeOH in DCM as the solvent.  The reaction mixture was then purified by 
column chromatography using a minimal amount of silica.  The solvent system which 
allowed for optimal separation was 7% MeOH in DCM.  Solvents were removed in the 
rotovap to yield 20 mg (28.6%) of product as a yellowish oil.
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Biological Data
 The following data is from SVR cell proliferation assays treated with the synthetic  
analogs of solenopsin A (Figure 15).  Hydrochloride salt forms of the benzamide analogs 
were diluted with 1 ml of EtOH each and then diluted again with 5 micro liters into 5 ml 
of media.  The endothelial cells were treated for 24 hours and then washed and counted.
Figure 15.  SVR Assay Results for Benzamide Analogs
45
 The SVR angiogenesis assays confirm that none of the synthetic benzamide 
compounds were anti-angiogenic.  For purposes of comparison the antiangiogenic 
bioactivity of solenopsin A, subject to the SVR assay, is again presented (Figure 16).  
Given the main structural feature of solenopsin A is the undecyl side-chain at the 6 
position of its piperidine ring, it is likely the structural component responsible for the 
observed antiangiogenic activity.  The synthetic long-chain n-alkyl analog, 2-methyl-6-
nonadecylpiperidine, is currently under consideration for testing in the SVR angiogenic 
assay.
Figure 16.  Previous SVR Assay Results of Solenopsin A
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